Takeda receives positive chmp opinion for vedolizumab iv for the treatment of active chronic pouchitis

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) announced today that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has recommended the approval of intravenous (iv) vedolizumab for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch-anal anastomosis (ipaa) for ulcerative colitis (uc), and have had an inadequate
TAK Ratings Summary
TAK Quant Ranking